Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B

Study Overview
=================
Brief Summary
-----------------
Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end stage liver disease who are not severely ill. Recently particular polymorphisms of IL-28B gene were reported to correlate with histological recurrence and antiviral treatment response after orthotopic liver transplantation for hepatitis C. Similar results have not been described yet in living donor liver transplant patients. There is data suggesting slightly inferior outcomes in living donor liver transplants when done for hepatitis C. The investigators postulate that such inferior outcomes may be related to IL28 polymorphism concordance (i.e., unfavorable recipient polymorphism patients receive similarly unfavorable polymorphism livers from their relatives).

Official Title
-----------------
Post Transplant Course of Hepatitis C Patients After Living Donor Liver Transplant in Association With Interleukin 28 B

Conditions
-----------------
Hepatitis C

Intervention / Treatment
-----------------
* Genetic: Interleukin 28B genotype


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who received a living donor liver transplant for chronic hepatitis C who are 18 year or older Patients who donated part of their liver to patients suffering from chronic hepatitis C. Donors must be 18 years or older Exclusion Criteria: Patients who are not willing to sign the consent Inability to obtain liver specimen (recipients) Inability to obtain blood sample (donors)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Liver transplant recipeints<br>Patients suffering from chronic hepatitis C that required a living donor liver transplant. | Genetic: Interleukin 28B genotype<br>* Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)<br>|
| Liver Donors<br>Patients who donated part of their liver to a patient suffering from chronic hepatitis C | Genetic: Interleukin 28B genotype<br>* Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sustained virological response after living donor liver transplant | Determine if sustained virological response is achieved after liver transplantation for hepatitis C with antiviral therapy (rivabirin and pegelated interferon) based on patient IL28B genotype | 12-24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Liver retransplantation | Determine the need of liver retransplantion based on the IL 28B genotype | 1-24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
End stage liver disease, Living donor liver transplantation, Hepatitis C, Interleukin 28B